FIELD: veterinary science; biotechnology.
SUBSTANCE: invention relates to veterinary virology and biotechnology. Described is an agent for preventing COVID-19 for carnivores. Contains an active substance and a target additive, according to the invention, as an active substance, it contains inactivated antigen material from the strain “version B” of the virus SARS-CoV-2 of coronavirus infection, preferably reproduced in a Vero C1008 cell culture and deposited in the collection of strains of the Federal State Budgetary Institution “48 Central Research Institute” of the Ministry of defense of Russia under registration number: 1199 — FGBU "48 TsNII" of the Ministry of defense of Russia, and target additive: 3% aluminum hydroxide gel, taken in volume ratio, %: 50.0÷50.0, respectively, and in amounts providing protective immunogenic activity of the antigen in the body of carnivores after administration of the target preparation.
EFFECT: invention extends the range of products for preventing coronavirus infection.
3 cl, 2 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
| TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
